The Board of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announced the spin-off of Biohaven Research Ltd. for on May 9, 2022. As per the transaction, Biohaven common shares will receive one common share of SpinCo for every two common shares of Biohaven held as of the record date. As of September 18, 2022, Biohaven Pharmaceutical Holding Company Ltd. announced record date for the transaction is September 26, 2022. The transaction is subject to shareholders approval and is approved by board of directors of Biohaven Pharmaceutical Holding Company Ltd. Sullivan & Cromwell LLP acted as legal advisor to Biohaven Pharmaceutical Holding Company Ltd. and Biohaven Research Ltd. The registration statement on Form 10 filed by Biohaven with the Securities and Exchange Commission in connection with spin-off became effective on September 22, 2022. The distribution date for the spin-off is expected to be early in the fourth quarter of 2022.

The Board of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) completed the spin-off of Biohaven Research Ltd. for on October 3, 2022.